Growth Stock Analytics-High EPS and Relative Strength Stock Market Trading System Growth Stock Analytics-High EPS and Relative Strength Stock Market Trading System
Growth Stock Investing and Trading for Stock Market Investors - Since 1996 | MyStockScreen.com | Home | Join Now | Member Login | Refer a Friend | Contact Us
Your Best Source For Top Stock Picks, Stock Rankings, Stock Screening, Swing Trading, Market Direction and More...
HI-EPSRS
Screener
My Watch
List
Market
Direction
Industry
Map
My
Account
Help Logout
Symbol:
Enter Symbols Separated By Spaces.
Download All Symbols To Text/CSV

Top Picks Watch List
Dist.Days: SPY:4 DOW:4 QQQ:2

GSA Live Portfolio:
FNSR PRO
2022-11-08: We have a signal to move out of CASH and into FBSOX....Read more

HI-EPSRS Database Search Results   

Search Results      Stocks 1 through 1 of 1 shown        Download Search Results Symbols To Text/CSV

G1 Therapeutics Inc (GTHX)
Vital Signs
GSA
Rank

Stock Ranking
Earnings
Consistency

EPS Consistency Ranking

0.0/1.0
Sales
Consistency

Sales Consistency Ranking

0.0/1.0
Looks Like
A Winner?

Looks Like A Winner Ranking

4/10
Entry Risk
Above Support

Price Above Stop Loss Ranking

5%
Group
Action

Group Action Ranking

1
"Must Have"/Timing Factors
GSA
70.57
Acc Dist
0.59
Disc
0.00%
Avg Vol
118,100
Liquidity
0.47%
Below High
27.38%
Group Action
1
3-Month Trends of Key Indicators:
Fundamental/Technical Factors
Qrtly EPS
N/A%  N/A%
EPS Growth
0%
Sls Growth
0%
Proj Growth
N/A %
Anal. Rank
4.69
Shares
28.3M
Instit
43%
3-Month Trends of Key Indicators:
Looks Like a Winner?
GTHX looks better than most Top Picks Winners* in 4 out of 10 key factors.
Accum/Dist: 0.59 (median winner: 1.53)
Above 40wkMA: 57% (median winner: 35%)
Instit. Ownership: 43% (median winner: 63%)
Liquidity: 0.47% (median winner: 1.18%)
Group Action: 1 (median winner: 20)
GSA Rank: 70.57 (winner: 75.66)
Sales Growth: 0% (median winner: 28%)
Below 52wk High: 27.38% (winner: 3.30%)
Relative Strength: 83 (winner: 96)
Avg Qrtly EPS: 0% (median winner: 68%)
Industry Group: 1. Not Available

Instit.   Insiders   Yahoo   Zacks   MSN   Google Finance   Daily Charts   Web Site

G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates.

  • [$$] Triggering a Debt Bomb Sat, 11 Nov 2017 05:01:00 +0000
    Review | Dates to Watch For | Follow Up | U.S. Economic Calendar | Consensus Estimates | Coming Earnings | Coming U.S. Auctions It’s more than a little curious that conservative politicians, who once espoused conservative principles with respect to the federal debt, have been notably absent from the debate over tax reform. The situation, already dire, has worsened considerably in the roughly two months since President Donald Trump cut a deal with Democratic congressional leaders Nancy Pelosi and Chuck Schumer.
  • G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights Wed, 08 Nov 2017 12:30:00 +0000
    Barclay Phillips appointed Chief Financial Officer and SVP, Corporate Development. Management reaffirms expectation of topline data from Phase 2 a trial of trilaciclib in first-line small-cell lung cancer ...
  • G1 Therapeutics Makes Key Executive Appointments Wed, 08 Nov 2017 12:00:00 +0000
    Barclay Phillips appointed Chief Financial Officer and Senior Vice President, Corporate Development. Chandra Lovejoy named Vice President, Global Regulatory Affairs. RESEARCH TRIANGLE PARK, N.C., Nov. ...
  • G1 Therapeutics to Present at Stifel 2017 Healthcare Conference Tue, 07 Nov 2017 13:00:00 +0000
    RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2017-- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview ...
  • G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response Mon, 06 Nov 2017 12:00:00 +0000
    RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2017-- G1 Therapeutics, Inc., a clinical-stage oncology company, announced the publication“ CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation,” ...
  • G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes Mon, 18 Sep 2017 11:30:00 +0000
    RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2017-- G1 Therapeutics, Inc., a clinical-stage oncology company, today announced that it has been added to the Russell 2000 ®, Russell 3000 ®, and Russell Microcap ...
  • Retail Investors: Your IPOs Are Here Fri, 09 Jun 2017 14:42:48 +0000
    Imagine a crowded subway station. It’s rush hour and everyone’s got somewhere to be. There’s a huge clamor to get on the next train. When it does eventually arrive, it’s a free-for-all. Elbows are flying. ...
  • IPOs This Week: Software Maker Appian Plus 3 More Hopefuls Sun, 21 May 2017 14:29:11 +0000
    Four IPOs on the calendar ahead of the Memorial Day holiday weekend: two tech firms, one blank-check company, and one cable TV operator.

Stock Research
Weekly-1Yr Daily-3Mo Daily-6Mo Daily-1Yr
Daily-6Mo w/2-ATR Stops 3-ATR 4-ATR
Daily-1 Yr (opens in new window)
(Larger Charts. ATR=Average True Range)

Stock Research
Rel Str Acc/Dist Grp Action Instit Disc%

Quarterly EPS GrowthQuarterly Sales Growth
GTHX EPS/Sales Growth GTHX vs. Peers



*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Copyright © 1996-2024 Growth Stock Analytics, LLC. All rights reserved.  Site Map | Privacy Policy | Contact Us